Related Experiment Video
Updated: Jan 24, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
ADORA2A Polymorphisms Influence Methotrexate Adverse Events in Rheumatoid Arthritis
Nadja Kobold1, Barbara Jenko1, Matija Tomšič2,3
1Institute of Biochemistry, Pharmacogenetics Laboratory, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Background:
Methotrexate is the most frequently administered first-line treatment for rheumatoid arthritis (RA). The disease-modifying effects of methotrexate are mainly associated with enhanced release of free adenosine. The downstream anti-inflammatory effects of adenosine are mediated via its binding to adenosine receptor 2A (ADORA2A) and 3 (ADORA3). Many clinically important single nucleotide polymorphisms (SNPs) were reported in ADORA2A and ADORA3 genes.
Objectives:
To investigate whether tagging ADORA2A and ADORA3 polymorphisms influences methotrexate treatment in RA.
Methods:
In total, 212 RA patients treated with methotrexate were genotyped for tagging ADORA2A (rs2298383, rs8141793, rs2236624, rs5751876, rs35320474, and rs17004921) and ADORA3 SNPs (rs2298191, rs1544223, rs78594984, rs35511654, rs2229155, rs3393, and rs3394).
Results:
RA patients who carried ADORA3 rs35511654 G allele showed a tendency toward better response to methotrexate treatment (P = 0.054). Carriers of ADORA2A polymorphic allele rs2298383 (P = 0.011), rs2236624 (P = 0.027), rs5751876 (P = 0.018), and rs35320474 (P = 0.026) were less likely to experience methotrexate induced adverse events. All associations remained significant after adjustment for clinical factors. The effects of these polymorphisms were also significant in haplotype analyses.
Conclusions:
Polymorphisms in the ADORA2A gene may influence methotrexate treatment response and may be considered as a potential biomarker for methotrexate treatment in rheumatoid arthritis.
Insights
Single nucleotide polymorphisms in ADORA2A and ADORA3 genes may influence rheumatoid arthritis treatment with methotrexate. Certain ADORA2A gene variants are linked to fewer adverse events, suggesting potential as biomarkers for methotrexate therapy.
Area of Science:
- Pharmacogenomics
- Rheumatology
- Molecular Biology
Background:
- Methotrexate is a primary treatment for rheumatoid arthritis (RA), working by increasing adenosine levels.
- Adenosine's anti-inflammatory effects are mediated through adenosine receptors 2A (ADORA2A) and 3 (ADORA3).
- Genetic variations, specifically single nucleotide polymorphisms (SNPs) in ADORA2A and ADORA3, are common and may impact drug response.
Purpose of the Study:
- To determine if specific tagging polymorphisms in the ADORA2A and ADORA3 genes affect patient response to methotrexate treatment for RA.
- To identify potential genetic biomarkers for predicting methotrexate efficacy and adverse events in RA patients.
Main Methods:
- Genotyping of 212 RA patients treated with methotrexate for selected tagging SNPs in ADORA2A and ADORA3 genes.
- Analysis of associations between specific SNPs (e.g., ADORA3 rs35511654, ADORA2A rs2298383, rs2236624, rs5751876, rs35320474) and treatment outcomes.
- Statistical analysis, including adjustments for clinical factors and haplotype analyses, to confirm significance.
Main Results:
- A trend towards better methotrexate response was observed in RA patients with the ADORA3 rs35511654 G allele (P = 0.054).
- Carriers of specific ADORA2A polymorphic alleles (rs2298383, rs2236624, rs5751876, rs35320474) showed a significantly lower likelihood of experiencing methotrexate-induced adverse events (P < 0.05).
- All identified associations remained statistically significant after adjusting for clinical factors and were supported by haplotype analyses.
Conclusions:
- Polymorphisms within the ADORA2A gene appear to influence the effectiveness and tolerability of methotrexate treatment in rheumatoid arthritis.
- These ADORA2A gene variants show promise as predictive biomarkers for optimizing methotrexate therapy in RA patients.
- Further research into ADORA2A and ADORA3 polymorphisms could lead to personalized treatment strategies for rheumatoid arthritis.
More Related Videos
09:31Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients
Published on: October 16, 2016
06:31Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis
Published on: October 6, 2023
Related Concept Videos
Local Anesthetics: Adverse Effects
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
Single Nucleotide Polymorphisms-SNPs
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Integration of Synaptic Events